BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance? Cancers (Basel) 2020;12:E774. [PMID: 32218226 DOI: 10.3390/cancers12040774] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: 'Beyond the T cell'. J Immunother Cancer 2021;9:e001460. [PMID: 33468555 DOI: 10.1136/jitc-2020-001460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
2 Hajifathali A, Parkhideh S, Kazemi MH, Chegeni R, Roshandel E, Gholizadeh M. Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted! J Cell Physiol 2020;235:9080-97. [DOI: 10.1002/jcp.29769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
3 Fiore PF, Vacca P, Tumino N, Besi F, Pelosi A, Munari E, Marconi M, Caruana I, Pistoia V, Moretta L, Azzarone B. Wilms' Tumor Primary Cells Display Potent Immunoregulatory Properties on NK Cells and Macrophages. Cancers (Basel) 2021;13:E224. [PMID: 33435455 DOI: 10.3390/cancers13020224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kaweme NM, Zhou F. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol 2021;12:683381. [PMID: 34220833 DOI: 10.3389/fimmu.2021.683381] [Reference Citation Analysis]
5 Gutiérrez-hoya A, Soto-cruz I. Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins. Cells 2020;9:2297. [DOI: 10.3390/cells9102297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Damele L, Amaro A, Serio A, Luchetti S, Pfeffer U, Mingari MC, Vitale C. EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells. Cancers (Basel) 2021;13:319. [PMID: 33467134 DOI: 10.3390/cancers13020319] [Reference Citation Analysis]